Imidazoquines as Antimalarial and Antipneumocystis Agents†

Nuno Vale,‡ Miguel Prudêncio,§ Catarina A. Marques,§ Margaret S. Collins,‡ Jiri Gut,‡ Fátima Nogueira, # Joana Matos,§ Philip J. Rosenthal,† Melanie T. Cushion,†§ Virgílio E. do Rosário, # Maria M. Mota,§ Rui Moreira,§ and Paula Gomes*†

†Ciqup—Centro de Investigação em Química da Universidade do Porto, Departamento de Química, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre 687, P-4169-007 Porto, Portugal, ‡Unidade de Malária, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, P-1649-028 Lisboa, Portugal, # Research Services, Veterans Affairs Medical Center, Cincinnati, Ohio 45220, †Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati, Ohio 45267-0560, *Department of Medicine, San Francisco General Hospital, University of California, California 94118, §Centro de Malária e Outras Doenças Tropicais, IHMT, Universidade Nova de Lisboa, P-1349-008 Lisboa, Portugal, and ^iMed.UL, CECF, Faculdade de Farmácia, Universidade de Lisboa, P-1600-083 Lisboa, Portugal

Received May 28, 2009

Peptidomimetic imidazolidin-4-one derivatives of primaquine (imidazoquines) recently displayed in vitro activity against blood schizonts of a chloroquine-resistant strain of Plasmodium falciparum. Preliminary studies with a subset of such imidazoquines showed them to block transmission of P. berghei malaria from mouse to mosquito and be highly stable toward hydrolysis at physiological conditions. This prompted us to have deeper insight into the activity of imidazoquines against both Plasmodia and Pneumocystis carinii, on which primaquine is also active. Full assessment of the in vivo transmission-blocking activity of imidazoquines, in vitro tissue-schizontocidal activity on P. berghei-infected hepatocytes, and in vitro anti-P. carinii activity is now reported. All compounds were active in these biological assays, with generally lower activity than the parent drug. However, imidazoquinones’ stability against both oxidative deamination and proteolytic degradation suggest that they will probably have higher oral bioavailability and lower hematotoxicity than primaquine, which might translate into higher therapeutic indexes.

Introduction

8-Aminoquinolines (8-AQ)§ are an important class of antimicrobial agents, with important roles in the treatment of malaria and Pneumocystis infection.1 Considering malaria, primaquine (1, Scheme 1) is still the only clinically available 8-AQ active against both gametocytes, responsible for disease transmission between the human host and the mosquito vector, and all exoerythrocytic forms (EEFs) of Plasmodia, including the liver hypnozoites responsible for relapses of vivax and ovale malarias.2–3 Primaquine (PQ) is also useful for the treatment of Pneumocystis infections5 caused by Pneumocystis jirovecii (formerly P. carinii f. sp. hominis8–10), which is a common cause of pneumonia in immunocompromised individuals and frequently the first serious illness encountered by HIV-infected patients.8–11 P. jirovecii also infects other immunocompromised individuals such as those undergoing cancer therapy and organ and bone marrow transplants.12 Unfortunately, PQ has low oral bioavailability because it is rapidly metabolized to the inactive metabolite carboxyprimaquine (2, Scheme 1) by oxidative deamination13,14 and presents blood toxicity, namely hemolytic anemia after primary induction of methemoglobinemia.3,4,15–17 Hematotoxicity is greatest in those with deficiency in glucose-6-phosphate dehydrogenase (6GPD) and is further aggravated by the need of frequent administration of high PQ doses in order to compensate for its low oral bioavailability.1–3 We previously reported that N-acylation of PQ with amino acids or dipeptides (3, Scheme 1) leads to active structures not susceptible to oxidative deamination to 2 but sensitive to degradation by amino- and endopeptidases.15 We now set out to explore the effect of introducing an imidazolidin-4-one trans

doi:10.1021/jm900738c

Published on Web 10/02/2009

© 2009 American Chemical Society
moiety in such N-acyl-PQ derivatives on the stability and bioactivity of the resulting compounds. Imidazolidin-4-one structures are often used to protect the N-terminal residues of peptides and peptidomimetics as well as to mimicize the amino acid proline. In this context, we prepared imidazolidin-4-ones 4 (Scheme 1) and found them to be promising therapeutic agents given their significant activity in blocking the transmission of \( P.\) berghei malaria from mice to mosquitoes, remarkable stability in pH 7.4 buffer and human plasma, and overall activity profile comparable to that of the parent drug against \( P.\) falciparum and \( P.\) carinii.

In view of initial promising results, we undertook the \( N^1\)-acylation of imidazolidin-4-ones 4 with amino acids, i.e., the preparation of structures 5 (Scheme 1) aimed at (i) fully suppressing hydrolysis of the imidazolidin-4-one ring through \( N^1\)-acylation of its N-1 nitrogen, (ii) increasing the compounds’ aqueous solubility by insertion of a basic amino acid group, and (iii) potentially increasing the compounds' antimalarial activity, given the relevant role usually attributed to the basic amino group of PQ.

A set of different structures 5, where the amino acids’ side chains (\( R_1 \) and \( R_2 \)) were varied, was prepared in order to check for the influence of these substituents on compound properties. Preliminary biological evaluation of compounds 5 demonstrated blood-schizontocidal activity against a chloroquine-resistant strain of \( P.\) falciparum as well as the ability to block transmission of \( P.\) berghei malaria between Balb/C mice and Anopheles stephensi mosquitoes. These results prompted us to further evaluate compounds 5 as antimalarial tissue-schizontocides and against \( P.\) carinii.

**Results and Discussion**

Chemistry. Compounds 4 were obtained and further \( N^1\)-acylated by previously reported methods through the synthetic route depicted in Scheme 2. Briefly, once prepared as previously described, imidazolidin-4-one precursors 4 were coupled to \( N^2\)-Boc-protected amino acids (BocAAOH) by means of a carbodiimide (diisopropylcarbodiimide, DIC) as condensation agent, in the presence of 1-hydroxybenzotriazole (HOBt) as auxiliary nucleophile. Boc was then removed from the condensation product by acidolysis with trifluoroacetic acid (TFA), yielding the target compounds 5 in good yields and with correct spectroscopic data. It is worth mentioning that bulky \( R^1 \) side chains impair imidazolidin-4-ones 4, which limited the synthesis of structures 5 to those where \( R^1 \) was either H or Me (respectively, glycine and alanine derivatives). Nonetheless, our previous work has shown that \( R^1 \) substituents on imidazolidin-4-ones 4 (i) should be small (H, Me) for higher transmission blocking activities and (ii) do not have a marked influence on compounds activity against both blood-stage \( P.\) falciparum or \( P.\) carinii. Bulky substituents on the imidazolidin-4-one’s C-2 carbon are also detrimental toward \( N\)-acylation, so only propanone-derived imidazolidin-4-ones are efficiently \( N\)-acylated. Nevertheless, insertion of larger substituents on the imidazolidin-4-one’s C-2, as those previously reported by us, would probably lead to a decreased water-solubility of final compounds 5. So, structural diversity of the latter was achieved by varying the second amino acid side chain (\( R^2 \), see Table 1) in order to check for the influence of this substituent on compound’s bioactivity.

The \( N\)-acetyl and \( N,N^1\)-diacetyl imidazolidin-4-one derivatives 6 and 7, also included in the present study for comparison purposes, were prepared by reacting 4 (\( R^1 = H, R^2 = R^3 = Me \)) with acetic anhydride (5 mol equiv), HOBt, and DIC in \( N,N\)-dimethylformamide (DMF) and in refluxing neat acetic anhydride (20 mol equiv), respectively.

**Biology. Antiplasmodial Activity and Cytotoxicity.** All compounds 5 were evaluated in vitro antimalarial activity against the chloroquine-resistant \( P.\) falciparum strain W2 (Table 1). Compound toxicity was evaluated by assessing effects on the viability of A549 human adenocarcinoma epithelial lung cells. Inspection of the data in Table 1 allows the following observations:

1. The in vitro antimalarial activity of compounds 5 is not significantly affected by the nature of the amino acid

---

**Scheme 2. Synthetic Route to Imidazoquines 5 and Their Acetyl Analogues 6 and 7**

\[ \text{Reagents and conditions: (i) 1 equiv BocAAOH, 1.1 equiv DIC, 1.1 equiv HOBt, 1 equiv triethylamine (TEA), dichloromethane (DCM), 0°C – rt; (ii) TFA, rt, 30% aq Na}_2 \text{CO}_3 \text{ extraction with CHCl}_3 \; (iii) excess propanone, 1 equiv TEA, molecular sieves, refluxing MeOH; (iv) 5 equiv BocAAOH, 5 equiv DIC/HOBt, 3 equiv TEA, DMF, –10°C – rt, inert atmosphere; (v) TFA/DCM 30%, rt, followed by Na}_2 \text{CO}_3 \text{ aq 30% and extraction with DCM; (vi) 5 equiv Ac}_2 \text{O, 5 equiv DIC/HOBt, 3 equiv TEA, DMF, –10°C – rt, inert atmosphere; (vii) refluxing neat Ac}_2 \text{O (20 equiv).} \]
residue at the imidazolidin-4-one’s N-1 atom. For example, the glycine derivative 5a (R² = H) is equipotent to its leucine counterpart, 5d (R² = i-Bu) and only ∼2 times more active than its methionine counterpart, 5f (R² = CH₂CH₂SMe).

The activity of compounds 5 is also not significantly affected by the nature of the R¹ substituent at the C-5 position of the imidazolidin-4-one moiety, as indicated by the similar IC₅₀ values for compounds 5a and 5h. This result contrasts sharply with that of precursors 4, in which the incorporation of a methyl group at C-5 leads to complete loss of activity (4a vs 4b).²⁸

Acetylation of the imidazolidin-4-one’s N-1 atom leads to complete loss of activity (e.g., 6 vs 5a), suggesting that the presence of a basic amino group is a major requirement for antimalarial activity. This result is in line with previous reports on the importance of such groups for the antimalarial activity of 8-aminoquinolines.¹⁸,³¹,³²

In general, compounds 5 displayed greater cytotoxicity than PQ against A549 cells, with the exception of 5a and 5h (i.e., the third most active and the most active compounds in the series, respectively), which showed no toxicity in this assay. Compound 5d also presented a favorable cytotoxicity/antimalarial ratio of 3.5.

Overall, these results suggest that the antimalarial activity of compounds 5 benefits from the N¹-acetylation of the imidazolidin-4-one ring with an amino acid. This fact may be partly due to the presence of the primary amino group brought by the inserted amino acid residue. This hypothesis is strengthened by the fact that N-acetylated derivatives 6 and 7 were found to be devoid of blood-schizontocidal activity.

### Anti-Plasmodium Liver Stage Activity

Given the tissue-schizontocidal activity of PQ and the fact that compounds 4 and 5 presented biological properties similar to those of the parent drug, it was predicted that the two sets of PQ imidazolidin-4-ones would be similarly active against liver forms of *Plasmodia*. To assess the ability of compounds 5 to inhibit the development of *P. berghei* schizonts in human hepatoma cells, we employed a recently described fluorescence activated cell sorting (FACS)-based method.³³ This method is based on the measurement of the fluorescence of Huh-7 cells, a human hepatoma cell line, following infection with GFP-expressing *P. berghei* sporozoites. At a given time after infection, the percentage of parasitized cells is given by the percentage of GFP-positive events (Figure 1A). Because GFP expression is under the control of the house-keeping EF1α promoter, the extent of intracellular development is proportional to the number of GFP copies in the cell, measured as the intensity of fluorescence (Figure 1A). The hepatic anti-plasmodial activity of compounds 5 was monitored by measuring infection of Huh-7 cells incubated with various concentrations of each, 48 h after sporozoite addition. The presence of these compounds decreased the number of GFP positive Huh-7 cells to different extents when compared with control values, albeit less so than the parent PQ (Figure S1 in Supporting Information). Most importantly, all compounds 5 displayed a marked, dose-dependent effect on parasite development (Figure 1B; Table 1). The IC₅₀ values of all the compounds in terms of their ability to impair the development of *P. berghei* liver schizonts were determined following the process depicted in Figure 1C. Although IC₅₀ values for compounds 5 were higher than that of PQ, several compounds displayed marked antimalarial activity, with their ranking following the order 5b ≈ 5e < 5c < 5a ≈ 5g < 5h < 5d < 5f.

### Table 1. Cytotoxicity, Anti-*Pneumocystis* Activity, and Antiplasmodial Activity of Compounds 1, 4a,b, 5a–h, 6, and 7 against Blood-Stage *P. falciparum* W2 and Liver-Stage *P. berghei*

<table>
<thead>
<tr>
<th>compd</th>
<th>R¹</th>
<th>R²</th>
<th>IC₅₀ (µM)</th>
<th>activity against blood stage forms</th>
<th>activity against liver stage forms</th>
<th>anti-<em>P. carinii</em> activity</th>
<th>cytotoxicity (A549 cells)²⁰</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IC₅₀ (µM)</td>
<td>24 h</td>
<td>48 h</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.3</td>
<td>2</td>
</tr>
<tr>
<td>4a</td>
<td>H</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9.1</td>
<td></td>
</tr>
<tr>
<td>4b</td>
<td>Me</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;50²⁰</td>
<td></td>
</tr>
<tr>
<td>5a</td>
<td>H</td>
<td>H</td>
<td></td>
<td></td>
<td></td>
<td>6.7</td>
<td>22</td>
</tr>
<tr>
<td>5b</td>
<td>H</td>
<td>CH₃</td>
<td></td>
<td></td>
<td></td>
<td>8.0</td>
<td>10</td>
</tr>
<tr>
<td>5c</td>
<td>H</td>
<td>CHMe₂</td>
<td></td>
<td></td>
<td></td>
<td>7.9</td>
<td>17</td>
</tr>
<tr>
<td>5d</td>
<td>H</td>
<td>CH₂CHMe₂</td>
<td></td>
<td></td>
<td></td>
<td>6.3</td>
<td>24</td>
</tr>
<tr>
<td>5e</td>
<td>H</td>
<td>CH(Me)Et</td>
<td></td>
<td></td>
<td></td>
<td>8.7</td>
<td>13</td>
</tr>
<tr>
<td>5f</td>
<td>H</td>
<td>(CH₂)₃SMe</td>
<td></td>
<td></td>
<td></td>
<td>12.5</td>
<td>31</td>
</tr>
<tr>
<td>5g</td>
<td>H</td>
<td>CH₂Ph</td>
<td></td>
<td></td>
<td></td>
<td>9.9</td>
<td>21</td>
</tr>
<tr>
<td>5h</td>
<td>Me</td>
<td>H</td>
<td></td>
<td></td>
<td></td>
<td>5.5</td>
<td>21</td>
</tr>
<tr>
<td>6</td>
<td>H</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;10.0</td>
<td>ND</td>
</tr>
<tr>
<td>7</td>
<td>H</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;10.0</td>
<td>ND</td>
</tr>
</tbody>
</table>

*a* Drug activity scale: highly active, <0.01 µg/mL; very marked, <0.1 µg/mL; marked, 0.1–0.99 µg/mL; moderate, 1.0–9.9 µg/mL; slight, 10.0–49.9 µg/mL; inactive ≥ 50.0 µg/mL.⁴⁰

⁴⁰ Human epithelial lung adenocarcinoma cell line. Taken from reference 28.
Anti-Pneumocystis Activity. The antifolate combination of trimethoprim and sulfamethoxazole (TMP-SMX) has been used for both prophylaxis and treatment of pneumocystosis,34,35 but development of microbial resistance and allergic reactions against the sulfa component often require the use of alternative therapies, among which is PQ, used in combination with clindamycin.35 Previous work suggests that there is a synchrony between the structure—activity relationships (SARs) presented by PQ-related drugs for malaria and pneumocystosis.34,36—39 Therefore, imidazolidin-4-ones 5 were evaluated against P. carinii in an ATP detection assay based on the release of bioluminescence driven by ATP in a luciferin-luciferase mediated reaction.40,41 All compounds, as well as PQ, reduced the ATP pools in P. carinii in a dose- and time-dependent manner. The maximal effect for compounds 5 was seen at 72 h with IC50 values ranging from 7 to 52 μM, i.e., from moderate to slight activity in the usual scoring scale while PQ presented an IC50 of 3.5 μM at 72 h (Table 2). Activity values were converted to a dosage of 0.1 mg kg−1, the usual dosage of PQ, to allow for direct comparison of activity. 

Table 2. effect of compounds 1 and 5a,b,c−h on the sporogonic development of Plasmodium berghei ANKA in Anopheles stephensi

<table>
<thead>
<tr>
<th>compd</th>
<th>dose/μmol·kg−1</th>
<th>mean no. of oocysts per mosquito ± SEMa</th>
<th>% of infected mosquitoes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10</td>
<td>3.5 ± 1.2 *40.0</td>
<td></td>
</tr>
<tr>
<td>5a</td>
<td>10</td>
<td>1.1 ± 0.2 *42.5</td>
<td></td>
</tr>
<tr>
<td>5b</td>
<td>10</td>
<td>0.8 ± 0.3 *40.5</td>
<td></td>
</tr>
<tr>
<td>5c</td>
<td>10</td>
<td>9.7 ± 2.5 *67.9</td>
<td></td>
</tr>
<tr>
<td>5h</td>
<td>10</td>
<td>1.3 ± 0.3 *40.1</td>
<td></td>
</tr>
<tr>
<td>5e</td>
<td>10</td>
<td>4.9 ± 0.6 *83.3</td>
<td></td>
</tr>
<tr>
<td>5f</td>
<td>10</td>
<td>1.5 ± 0.5 *62.2</td>
<td></td>
</tr>
<tr>
<td>5g</td>
<td>10</td>
<td>1.2 ± 0.4 *47.1</td>
<td></td>
</tr>
<tr>
<td>5h</td>
<td>10</td>
<td>3.7 ± 1.2 *43.8</td>
<td></td>
</tr>
<tr>
<td>control</td>
<td>0</td>
<td>8.2 ± 1.2 *72.1</td>
<td></td>
</tr>
</tbody>
</table>

a Standard error of the mean.
was not significantly affected by the nature of the side chain at the terminal amino acid residue, i.e., R'. For example, compounds 5b (R' = Me), 5d (R' = iso-Bu), 5e (R' = sec-Bu), 5f (R' = CH₃CH₂SMe) had less than 3-fold variation in IC₅₀ values from compounds 5a–5g. The N¹-acetyl derivative 6, which is a desamino analogue of imidazoquines 5, although clearly much less active than the latter, did display some activity after 72 h. This result indicates that IC₅₀ values decrease over time and that all compounds assayed inhibit P. carinii development after 72 h, with the exception of the N', N'-diacetyl derivative 7. These results suggest that PQ’s secondary amino group attached to the quinoline’s C-8 has a role in antipneumocystis activity. Remarkably, the N¹-acetyl-imidazolidin-4-ones 5 showed activity as soon as 48 h after initiation of incubation, which represents an improvement over most of their imidazolidin-4-one precursors 4 that were only visibly active after 72 h. Moreover, at 72 h, most compounds 5 were slightly more effective than their precursors 4, as illustrated by comparison of compound 4.2 (R¹ = R² = R³ = CH₃; IC₅₀ at 72 h = 226 μM)²⁵ with its N¹-glycyl derivative 5h (IC₅₀ at 72 h = 52 μM).

The relative positions of the two amino acid building blocks (i.e., switching between R¹ and R²) also seems important, as shown by comparison of compound 5h with its isomer 5b (IC₅₀ at 72 h = 8.4 μM).

Overall, these data show a certain degree of parallelism between the antiplasmodial and antipneumocystis activities of 8-aminoquinolinic compounds, as N¹-acylation of imidazolidin-4-ones 4 (to yield 5) seems to be beneficial both for the blood-schizontocidal and for the antipneumocystis activity of these compounds. However, the most efficient compounds against P. falciparum were not those that ranked the best against P. carinii.

In Vivo Transmission-Blocking Activity. The potential of compounds 5 to inhibit the sporogonic cycle of Plasmodia within the mosquito gut was studied using a model consisting of Balb/C mice infected with P. berghei and Anopheles stephensi mosquitoes and compared to that of PQ.²⁶ The activity was measured by the percentage of mosquitoes with oocysts and the mean number of oocysts per infected mosquito (Table 2). Although this model cannot specifically attribute the drug effect to either gametocytocidal or sporontocidal activity, it can clearly show if a compound is effective at interrupting the transmission of the infection to mosquitoes by interference with the cycle in these insects.²⁶ Compounds were tested at 10 and 50 μmol·kg⁻¹ and, although none of them was particularly good at decreasing the percentage of infected mosquitoes, all of them were active at effectively reducing the mean number of oocysts formed per infected mosquito. Moreover, while none of them was superior to PQ at the highest dose, at the lowest dose two of them (5g, h) were comparable to and two others (5a, f) were better than the parent drug. Compound 5a significantly reduced (P < 0.05) the sporogonic development of the parasite at both doses tested, while compound 5b was inactive at 10 μmol/kg. Interestingly, 5e was clearly active but did not rank the best of the set, in contrast to its relative activity against liver-stage P. berghei. Results also show that there is no correlation between transmission-blocking and anti-P. carinii activities, as previously noticed for imidazolidin-4-one precursors 4.²⁸

Physicochemical Properties and Plasma Stability. Several parameters were calculated for imidazolidin-4-ones 5 in order to gain some insight to their drug-likeness: molecular weight, HBD, HBA, logP, logS, and Drug Score (see Table S1 in Supporting Information).⁴³,⁴⁴ All imidazoquines 5 have molecular weights below 500 Da (except for 5g that weighs 503 g/mol), less than five hydrogen bond donors (all compounds 5 have three HBD), less than 10 hydrogen bond acceptors (all compounds 5 have five HBA) and estimated⁴⁵,⁴⁶ octan-1-ol/water partition coefficients (logP) below 5 (Table S1, Supporting Information). While imidazolidin-4-one precursors 4a, b have slightly increased lipophilicities with respect to PQ, but at the expense of significantly decreased water-solubility, imidazoquines derived from Ala (5b, h) have only slightly reduced lipophilicity (logP respectively of 2.49 and 2.57, as compared to 2.76 for PQ) accompanied by a remarkable increment on their water-solubility (0.12 g/L as compared to 56.4 mg/L for PQ). Finally, drug scores were consistently higher for compounds 5 and 4a, b than that for the parent compound. We also determined the stability of compounds 5 in 80% human plasma,²⁶,²⁷ which was found to be remarkably high, with no degradation detected after three days of incubation. Importantly, stability was not affected by the substitution pattern at the terminal amino acid or the imidazolidin-4-one moiety. Such stability had already been reported on previous studies involving some of these imidazoquines and their precursors.²⁵–²⁷,⁴⁷,⁴⁸ Overall, these results suggest that the oral availability of compounds 5 is unlikely to be limited by compound stability.

Conclusions

Imidazoquines, i.e., peptidomimetic derivatives of PQ with general structure 5, are stable compounds that preserve the overall bioactivity pattern of the parent drug. Because of blockage of the aliphatic amine of PQ by insertion of the peptidomimetic carrier, structures 5 are not vulnerable to oxidative deamination, which is the main metabolic process behind the low oral bioavailability of PQ. On the other hand, the use of a peptidomimetic instead of a dipeptide carrier makes compounds 5 stable to proteolytic degradation by action of amino- or endopeptidases.

It is well established that the main problem of PQ, which is still the only drug in clinical use to treat hypnozoites of vivax and ovale malaria, is of metabolic nature, as metabolic transformations are behind both PQ’s low bioavailability and serious hematotoxicity, especially for people deficient in 6GPD. Consequently, even though most imidazoquines 5 were generally not as active as the parent PQ, their remarkable chemical and enzymatic stability, as well as preliminary data on their ADME properties, suggest that they are promising leads toward novel hydrolytically- and enzymatically stable drugs with therapeutic indices superior to that of primaquine, useful against malaria and pneumocystosis.

Experimental Section

Chemistry. For compound synthesis, N⁰-protected amino acids and N⁰-protected dipeptides from Bachem (Switzerland) were used. Solvents were of p.a. quality, from Merck (VWR International, Portugal). When required, solvents were previously dried with preactivated molecular sieves (4 Å) (Merck). Both thin layer chromatography (TLC) aluminum foil plates covered with silica 60 F₂₅₄ (0.25 mm) and silica-gel 60 (70–230 mesh ASTM) for preparative column chromatography were also from Merck. Other chemicals (DIC, HOBt, TEA, TFA) were from Sigma-Aldrich.
The purity degrees of all compounds were checked to be higher than 95%, as determined by HPLC using a Merck Hitachi ELITE LaChrom equipped with an L-2130 pump, an L-2200 autosampler, and an L-2455 diode-array detector. Samples were injected on a Merck Purospher STAR RP-18e 125 cm × 4.6 mm (5 μm) column equipped with a Merck Lichrocart precolumn (Merck, Germany). Analyses were run by either isocratic or gradient methods (see Supporting Information for details) at a 1 mL/min flow rate. Chromatograms recorded at 265 nm are given in the Supporting Information.

NMR spectra of compounds dissolved in deuterated chloroform (CDCl3), containing tetramethylsilane (TMS) as internal reference, were acquired on a Bruker AMX-300 spectrometer. Mass spectrometry (MS) was performed either by the matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) technique, on an Applied Biosystems Voyager STR-DE spectrometer using either anthracene or 2,5-dihydroxibenzoic acid (DHB) as adjuvant matrices, or by the electrospray ionization–ion trap (ESI-IT) technique on a Finnigan Surveyor LCQ DECA XP MAX quadrupole mass spectrometer.

**General Procedure for the Synthesis of Imidazooxazines 5a–h.**

The synthetic route followed is depicted in Scheme 2. Synthesis detailed procedures, percentage yields, and analytical/spectroscopic data for all test compounds, with the exception of 5e and its Boc-protected precursor Boc-5e, have been described elsewhere.25,26,29

Briefly, PQ (1) was coupled to the relevant Boc-protected amino acid to produce Boc-3, which was then deprotected by acidolysis to give the trifluoroacetic acid salt of 3 that was converted to the free base (3) by addition of 30%aq Na2CO3 until pH 10 was reached, followed by extraction with chloroform (Scheme 2 and respective legend).25,26 Each compound 3 (2 equiv) was then mixed with an excess (4 equiv) of propanone in dry methanol (10 mL) containing triethylamine (TEA, 2 equiv), and the mixture was refluxed for 3 days in the presence of 4 Å molecular sieves (1 g).25,26 The reaction was monitored by TLC and propanone was readded (2 equiv) once per day. The molecular sieves were removed by decantation and the solution was evaporated to dryness, producing an oily residue that was submitted to column chromatography on silica gel. The product was isolated as yellow–orange oil and correctly identified as the target imidazolidin-4-one 4 (Scheme 2).25,26

Compounds 4 (1 equiv) were dissolved in DMF (20 mL) containing TEA (3 equiv), and the mixture was stirred at −10 °C for 20 min under inert atmosphere. The appropriate Boc-protected amino acid (5 equiv) was added together with DIC (5 equiv) and HOBt (5 equiv), and the suspension was kept at −10 °C for further 4 h, under stirring. The temperature was then increased to 10 °C and thus maintained until the end of reaction (24 h by TLC). The solid was removed by vacuum filtration, and the filtrate was evaporated to dryness in vacuum at 90 °C, yielding a residue that was dissolved in 40 mL of DCM. This solution was washed three times with 15 mL portions of 10%aq NaHCO3, and the organic layer dried over anhydrous MgSO4 and evaporated to dryness. The residue was submitted to column chromatography on silica using DCM/acetone, to give the Boc-protected imidazooxazines, Boc-5, as yellow–orange oils presenting correct spectral data.26,27 Each compound Boc-5 was then dissolved in TFA at 30% in DCM, and the reaction was allowed to proceed for 2 h at room temperature. Then 30%aq Na2CO3 was added to the resulting trifluoroacetic acid salt of 5 until pH 10, and the supernatant oily layer formed was extracted six times with 10 mL portions of chloroform. The organic layers were pooled, dried over anhydrous MgSO4, and evaporated to dryness, yielding a chromatographically homogeneous yellow–

orange oils that were identified as the target structures 5.25,26

1-[N-(tert-Butyloxycarbonyl)isoleucyl]-3-(4-(6-methoxyquinolin-8-ylamino)pen-t-yl)-2,2-dimethylimidazolidin-4-one (Boc-5e).28b H NMR (400 MHz, CDCl3) δ 6.86–8.30 (m, 6H), 1.24 (3H, J = 6.4 Hz), 1.37 (3H), 1.54–1.53 (s, 6H), 1.82–1.58 (m, 7H), 3.27–3.10 (m, 2H), 3.61–3.55 (m, 1H), 3.82 (s, 2H), 3.97–3.91 (m, 1H), 4.01 (d, 1H, J = 15.0 Hz), 4.36 (d, 1H, J = 14.9 Hz), 4.97 (d, 1H, J = 9.0 Hz), 6.22 (d, 1H, J = 2.5 Hz), 6.26 (d, 1H, J = 2.5 Hz), 7.23 (d, 1H, J = 4.2, 8.3 Hz), 7.85 (dd, 1H, J = 1.6, 8.3 Hz), 8.45 (dd, 1H, J = 1.6, 4.1 Hz).13C NMR (100 MHz, CDCl3) δ 9.58, 13.93, 19.22, 22.91, 23.57, 23.71 + 24.34 + 24.60, 26.00, 26.82, 32.62 + 32.65, 35.94, 36.61, 38.39, 46.39, 47.14, 50.50, 53.76, 55.52, 78.36, 79.34, 90.32, 95.35, 120.41, 128.45, 133.35, 133.85, 142.86, 143.47, 154.22, 157.95, 164.35, 169.08. m/z [M + H]+ = 570.8003 (calcd 570.6355); [M + Na]+ = 592.7314 (calcd 592.3475).
(parasite line 259 cL2) sporozoites were obtained by disruption of the salivary glands of freshly dissected infected female *Anopheles stephensi* mosquitoes.

**Parasite Development Assays.** Intracellular parasite development was determined by measuring GFP intensity in cells infected with GFP-expressing *P. berghei* parasites by fluorescence-activated cell sorting (FACS), as previously described. Briefly, cell samples for FACS analysis were washed with 1 mL of phosphate buffered saline (PBS), incubated with 100 μL of trypsin for 5 min at 37 °C, and collected in 400 μL of 10% v/v FCS in PBS at the selected time points post sporozoite addition. Cells were then centrifuged at 0.1g for 5 min at 4 °C and resuspended in 150 μL of 2% v/v FCS in PBS. Cells were analyzed on a Becton Dickinson FACScalibur with the appropriate settings for the fluorophore used. Data acquisition and analysis were carried out using the CELLquest (version 3.2.1f1, Becton Dickinson) and FlowJo (version 6.3.4, FlowJo) software packages, respectively.

**In Vitro Anti-*P. carinii* Activity Assays.** *P. carinii* Organisms. For the ATP assays were obtained from chronically immunosuppressed Long Evans and Brown Norwegian rats housed under barrier conditions at the Cincinnati VA Medical Center (VAMC) and inoculated intratracheally with *P. carinii*. These were extracted and purified from the lungs of rats after 8–12 weeks of immunosuppression, enumerated, cryopreserved, and stored in liquid nitrogen. Typically, infected rat lungs yielded up to 2 × 10⁶ organism nuclei with the vast majority (about 95%) of the life cycle forms present as trophic forms with the remainder (about 5%) being composed of cysts. *P. carinii* preparations were evaluated for microbial contamination, ATP content, karyotype, and host cell content prior to use in the ATP assay.

**ATP Assay.** Isolated organisms used for ATP analyses were suspended in a supplemented RPMI 1640 medium containing 20% calf serum and other additives, pH 7.5–8.0, 380 μM, as previously described. Drugs were added to the culture medium in DMSO (the final concentration of DMSO was <0.2%, vol/vol), and 10⁵ organisms (as total nuclei) per mL were added to 1–2 mL of the culture medium in multiwell plates. For every assay, each drug concentration was assayed in triplicate using different organism isolation batches. The final ATP content was expressed as the average relative light units of nine values (three readings per well). To assess the effects of extended exposure to PQ and imidazoquinines, the ATP contents of cultures sampled at 24, 48, and 72 h of incubation at 35 °C were compared to the controls (vehicle). The solvent system used was a gradient of sodium acetate buffer (pH 4.75; 0.05 M) (A) and acetonitrile (B): 10⁻⁴ M triethylamine was added to the aqueous mobile phase in order to improve peak shape. The gradient was as follows: 0 min, 50% B; 4.5 min, 50% B; 5.0 min, 10% B; 20 min, 10% B, Elution was performed at a solvent flow-rate of 1 mL/min and a 15 mL/min nitrogen sparging was applied to remove dissolved gases. Chromatographic separation was monitored by UV detection at 265 nm. All analyses were performed at room temperature.

**Hydrolysis in Human Plasma.** Compounds 5 were incubated at 37 °C in human plasma (from heparinized blood of healthy donors) diluted to 80% (vol/vol) with pH 7.4 isotonic phosphate buffer. At appropriate intervals, aliquots were added to acetonitrile to quench the reaction and precipitate plasma proteins. These samples were centrifuged and the supernatant analyzed by the HPLC method described above for the presence of substrate and products.

**Acknowledgment.** This work was mainly supported by Fundação para a Ciência e a Tecnologia (FCT, Portugal) through projects PTDC/QUI/65142/2006, CONC-REEQ/275/QUI, REDE/1517/RMN/2005 to P.G. and PTDC-BIA-BCM-71920-2006 to M.P.N.V. thanks FCT for postdoctoral grant SFRH/BPD/48345/2008. P.G. and R.M. thank FCT for financial support to CIQUP and CECF research units, respectively. M.P. is a holder of a Ciência 2007 position of the Portuguese Ministry of Science. M.M.M. is a Howard Hughes Medical Institute International Scholar. P.J.R. was supported by grants from the National Institutes of Health and Medicines for Malaria Venture and is a Distinguished Clinical Scientist of the Doris Duke Charitable Foundation.

**Supporting Information Available:** HPLC traces for imidazoquinines 5, flow cytometry-based *Plasmodium* liver stage infection assay of dose-dependencies of percentage of infected cells, and preliminary ADME data for imidazoquinines 5. This material is available free of charge via the Internet at http://pubs.acs.org.

**References**


